Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Fleischmann

Showing results (111-120 of 190) with videos related to

Pageof 19
Sort By:
RMD Open|March 10, 2022
Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapyPeter C Taylor, Rieke Alten, Jose María Álvaro Gracia, et al.
RMD Open|April 17, 2018
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label studyRoy Fleischmann, Peter Winkle, Jesse Hall, et al.
RMD Open|May 28, 2024
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE studyRoy Fleischmann, Jerzy Swierkot, Sara K Penn, et al.
RMD Open|February 5, 2022
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE studyRoy Fleischmann, Eduardo Mysler, Louis Bessette, et al.
Arthritis Research & Therapy|June 12, 2020
Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studiesMark C Genovese, Roy Fleischmann, Alan Kivitz, et al.
Annals of the Rheumatic Diseases|June 12, 2023
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programmeRoy Fleischmann, Jeffrey R Curtis, Christina Charles-Schoeman, et al.
Arthritis and Rheumatism|November 13, 2003
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trialJohn C Davis, Désirée Van Der Heijde, Jurgen Braun, et al.
RMD Open|March 14, 2018
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label studyRoy Fleischmann, Peter Winkle, Jeffrey N Miner, et al.
Rheumatology (Oxford, England)|February 11, 2014
Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemiaRoy Fleischmann, Bradley Kerr, Li-Tain Yeh, et al.
Annals of the Rheumatic Diseases|August 13, 2014
Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an exampleRobert B M Landewé, Josef S Smolen, Michael E Weinblatt, et al.
Pageof 19

Showing results (111-120 of 190) with videos related to

Sort By:
Pageof 19
RMD Open|March 10, 2022
Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapyPeter C Taylor, Rieke Alten, Jose María Álvaro Gracia, et al.
RMD Open|April 17, 2018
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label studyRoy Fleischmann, Peter Winkle, Jesse Hall, et al.
RMD Open|May 28, 2024
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE studyRoy Fleischmann, Jerzy Swierkot, Sara K Penn, et al.
RMD Open|February 5, 2022
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE studyRoy Fleischmann, Eduardo Mysler, Louis Bessette, et al.
Arthritis Research & Therapy|June 12, 2020
Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studiesMark C Genovese, Roy Fleischmann, Alan Kivitz, et al.
Annals of the Rheumatic Diseases|June 12, 2023
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programmeRoy Fleischmann, Jeffrey R Curtis, Christina Charles-Schoeman, et al.
Arthritis and Rheumatism|November 13, 2003
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trialJohn C Davis, Désirée Van Der Heijde, Jurgen Braun, et al.
RMD Open|March 14, 2018
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label studyRoy Fleischmann, Peter Winkle, Jeffrey N Miner, et al.
Rheumatology (Oxford, England)|February 11, 2014
Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemiaRoy Fleischmann, Bradley Kerr, Li-Tain Yeh, et al.
Annals of the Rheumatic Diseases|August 13, 2014
Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an exampleRobert B M Landewé, Josef S Smolen, Michael E Weinblatt, et al.
Pageof 19